Personalized medicine: Risk prediction, targeted therapies and mobile health technology

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Hayes, Daniel F ^a   Markus, Hugh S ^b   Leslie, R D ^c   Topol, Eric J ^d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

Diabetes; Genetics; Mobile health; Oncology; Personalized medicine; Smartphone; Stroke; Targeted therapy

Indexed keywords

AMBULATORY CARE; ARTICLE; CANCER GROWTH; CANCER THERAPY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ENDOCRINOLOGY; HUMAN; INTENSIVE CARE UNIT; LAW; MEDICATION ERROR; MOBILE APPLICATION; MOBILE PHONE; MOLECULARLY TARGETED THERAPY; NEUROLOGY; ONCOLOGY; PERSONALIZED MEDICINE;

CELLULAR PHONE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TELEMEDICINE;

EID: 84896889851     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-37     Document Type: Article

References (19)

1. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 148:104-107.
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037. 10.1056/NEJM200104053441401, 11287972.
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multi-gene RT-PCR assay using fixed, paraffin-embedded tumor tissue to predict the likelihood of breast cancer recurrence in node negative, estrogen receptor positive, tamoxifen-treated patients. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
5. Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012, 30:2218-2226. 10.1200/JCO.2011.38.5740, 3397718, 22585699.
6. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med 2013, 5:196cm196.
7. Institute of Medicine Evolution of Translational Omics: Lessons Learned and the Path Forward 2012, Washington, DC: The National Academies Press, Institute of Medicine.
8. McShane L, Hayes DF. Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 2012, 30:4223-4232. 10.1200/JCO.2012.42.6858, 3504327, 23071235.
9. Markus HS. Stroke genetics: prospects for personalized medicine. BMC Med 2012, 10:113. 10.1186/1741-7015-10-113, 3521189, 23016624.
10. Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 2009, 8:38. 10.1186/1475-2840-8-38, 2723076, 19619327.
11. Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010, 26:239-244. 10.1002/dmrr.1092, 20503255.
12. Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia 2008, 51:921-925. 10.1007/s00125-008-0983-2, 18389212.
13. McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013, 36:237-244. 10.2337/dc12-0706, 3554278, 23033241.
14. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of non-insulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418. 10.1001/jama.2010.405, 20388897.
15. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S, ADVANCE Collaborative Group Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418. 10.1056/NEJMoa1003795, 20925543, ADVANCE Collaborative Group.
16. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS, American Diabetes Association, American College of Cardiology Foundation, American Heart Association Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. J Am Coll Cardiol 2009, 53:298-304. 10.1016/j.jacc.2008.10.008, 19147051, American Diabetes Association, American College of Cardiology Foundation, American Heart Association.
17. Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Puente DM, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD, on behalf of the Action LADA consortium Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 2013, 36:908-913. 10.2337/dc12-0931, 23248199, on behalf of the Action LADA consortium.
18. Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?. BMJ 2007, 8:508-512.
19. Topol E. The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care 2012, New York: Basic Books.